San Diego, CA (PRWEB) November 13, 2012
The annual Private Equity Compensation Survey is almost complete and participation is closing this week.
Investment professionals in venture capital and private equity are invited to participate and the online survey takes less than 10 minutes to complete.
The industry-leading effort enables investment professionals to provide direct input into the compensation benchmarks, avoiding the biases of service provider estimates and dated information. Eligible survey participants receive the final 2013 Private Equity Compensation Report (a $347.00 value) in return for their participation.
Private equity and venture capital professionals are invited to participate in the survey by visiting the Private Equity Compensation Survey website at http://www.pecompsurvey.com
"Hundreds of firms are represented both large and small," says David Kochanek, publisher of the Private Equity Compensation Report. "We've seen participation from professionals spanning the full range of experience and roles, including analysts, associates, VP's, CFO's and Managing Partners.”
The compensation survey uncovers industry benchmarks regarding carried interest (carry), work culture, bonuses, fund performance and job satisfaction.
Private equity and VC professionals are invited to participate in the survey at http://www.pecompsurvey.com and, once the data is collected and results published – participants will receive secure access to the Private Equity Compensation Report free of charge.
About The Survey
The Private Equity Compensation Survey is currently open to participants in the Private Equity and Venture Capital industries. Data is collected directly from private equity and venture capital partners and employees from firms of all sizes. Some of the firm participating in past surveys included: 3i, Actis, American Capital, Babson Capital Management, Bain Capital, BlackRock, Clairvest, CPP Investment Board, Deutsche Bank, EDC Equity, EdgeStone Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures, North Atlantic Capital, RBS, Safeguard Scientifics, SV Life Sciences and Time Warner Investments.